Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : mRNA-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sinopharm Unit Gets Ok For Clinical Trials Of mRNA Covid Vaccine
Details : Sinopharm's mRNA-based COVID-19 vaccine was developed using the traditional method, by means of an inactivated virus, in this case the coronavirus, which causes COVID-19 - is killed or modified in such a way that it is unable to replicate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : mRNA-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : ChromaDex, Inc
Deal Size : Undisclosed
Deal Type : Agreement
Details : Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.
Product Name : Tru Niagen
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
October 06, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : ChromaDex, Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Inactivated SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sinopharm's COVID Booster Reverses Antibody Decline, Enhances Cell-Based Responses - Study
Details : BBIBP-CorV vaccine is an inactivated SARS-CoV-2 vaccine (Vero cell), indicated the potential of BBIBP-CorV to provide cross-protection against other SARS-CoV-2 strains.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 17, 2021
Lead Product(s) : Inactivated SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China Grants Conditional Market Approval for Sinopharm CNBG’S COVID-19 Vaccine
Details : The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, Chinese equivalent of FDA.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 01, 2021
Lead Product(s) : Inactivated COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China's Sinopharm Says Data 'Better Than Expected" From Unit's COVID-19 Vaccine Trials
Details : Sinopharm's Vero cell is under Phase III randomized, double blind trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 Vaccines in healthy population aged 18 years old and above.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 11, 2020
Lead Product(s) : Inactivated SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBIBP-CorV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
COVID-19 Vaccine from China's Sinopharm Clears Animal Tests
Details : The vaccine candidate, dubbed BBIBP-CorV and made from an inactivated form of the virus, induced high levels of neutralizing antibodies against SARS-CoV-2—the virus behind COVID-19—in rodents, rabbits and monkeys without triggering any serious advers...
Product Name : BBIBP-CorV
Product Type : Vaccine
Upfront Cash : Inapplicable
November 06, 2020
Lead Product(s) : BBIBP-CorV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China's Sinopharm Starts Phase III Trial of COVID-19 Vaccine in Bahrain
Details : Sinopharm has begun Phase III clinical trials of a COVID-19 vaccine in Bahrain, after launching similar trials in the United Arab Emirates last month.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 08, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Beijing Institute of Biological Product
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MOHAP, in collaboration with Department of Health Abu Dhabi, DOH, has reviewed Sinopharm CNBG’s interim analysis of the phase III trials, which shows Beijing Institute of Biological Product’s inactivated vaccine to have 86 percent efficacy against CO...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 12, 2020
Lead Product(s) : Inactivated COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Beijing Institute of Biological Product
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sinopharm Shares Phase 2 Data On Inactivated Covid-19 Vaccine
Details : Sinopharm's inactivated COVID-19 vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy will require phase 3 trials.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 13, 2020
Lead Product(s) : Inactivated COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China's Sinopharm to Test Potential COVID-19 Vaccine in Brazil
Details : Sinopharm and Parana state have agreed to launch the fourth major COVID-19 vaccine trial in Brazil and will seek regulatory approval in the next two weeks, the Brazilian partners said on Wednesday.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 30, 2020
Lead Product(s) : Inactivated COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable